Alnylam Pharmaceuticals | ALNY - Ebit

Stock Price
305.54
Daily Change
-8.25 -2.63%
Monthly
-7.05%
Yearly
21.46%
Q2 Forecast
299.00

Alnylam Pharmaceuticals reported $29.4M in EBIT for its fiscal quarter ending in December of 2025.





Ebit Change Date
Acadia Pharmaceuticals USD 17.39M 18.36M Dec/2025
Agios Pharmaceuticals USD -121.58M 4.71M Dec/2025
Alnylam Pharmaceuticals USD 29.4M 59.36M Dec/2025
Amgen USD 3.96B 464M Dec/2025
Arrowhead Research USD 40.81M 17.01M Dec/2025
BioCryst Pharmaceuticals USD 260.38M 230.79M Dec/2025
BioMarin Pharmaceutical USD 198.39M 230.08M Dec/2025
Incyte USD 383.88M 47.44M Dec/2025
Ionis Pharmaceuticals USD -215M 54.82M Dec/2025
Moderna USD -857M 597M Dec/2025
Neurocrine Biosciences USD 227.9M 11.4M Dec/2025
Novartis USD 4.06B 413M Dec/2025
PTC Therapeutics USD -81.62M 85.11M Dec/2025
Regeneron Pharmaceuticals USD 898.6M 211.3M Dec/2025
Sanofi EUR 3.74B 2.23B Sep/2025
Sarepta Therapeutics USD -410.08M 347.2M Dec/2025
Takeda JPY 257.49B 568.56B Dec/2025
Tectonic Therapeutic USD -21.52M 374K Dec/2025
Ultragenyx Pharmaceutical USD -114M 56.89M Dec/2025
Vertex Pharmaceuticals USD 1.26B 24.5M Dec/2025
Xencor USD -53.63M 6.11M Dec/2025